Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Q-VaxCelerate
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Q-VaxCelerate is an investigational T cell epitope-based DNA vaccine designed for the prevention of Q fever, a zoonotic disease caused by the intracellular bacterium *Coxiella burnetii*. Developed by the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital in collaboration with EpiVax, the vaccine utilizes the iVAX computational toolkit to identify highly conserved T cell epitopes across various strains of the pathogen. Unlike the existing whole-cell inactivated vaccine (Q-Vax), which can trigger severe hypersensitivity reactions in individuals with prior exposure to *C. burnetii*, Q-VaxCelerate is engineered to induce robust cellular immunity without the risk of adverse inflammatory responses associated with whole-cell components. The vaccine is currently being evaluated in early-stage clinical trials to assess its safety and immunogenicity in humans.
- Other names
- Q fever T-cell vaccine
02
Targets
HLA-DR (Human leukocyte antigen DR)
Beyond the preview
Go deeper on Q-VaxCelerate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Q-VaxCelerate.